^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
vibostolimab/pembrolizumab (MK-7684A)
i
Other names: MK-7684A, MK-7684/MK-3475, MK7684A, MK 7684A, MK7684/MK3475, MK 7684/MK 3475
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
PD1 inhibitor, TIGIT inhibitor
Related drugs:
13d
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=296, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
2ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
2ms
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=320, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2030 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
3ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2026 --> Sep 2025
Trial completion date
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
4ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2025 --> Sep 2026
Trial completion date
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
4ms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov)
P2, N=613, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • albumin-bound paclitaxel • oxaliplatin • vibostolimab/pembrolizumab (MK-7684A)
6ms
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
P2, N=302, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Apr 2026 | Trial primary completion date: Jun 2026 --> May 2025
Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
|
MSI (Microsatellite instability)
|
MSI-H/dMMR • RAS wild-type
|
Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
7ms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov)
P2, N=613, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2026 --> Aug 2025 | Trial primary completion date: Aug 2026 --> Aug 2025
Trial completion date • Trial primary completion date • Pan tumor
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • albumin-bound paclitaxel • oxaliplatin • vibostolimab/pembrolizumab (MK-7684A)
7ms
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
P3, N=1594, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2031 --> Aug 2025
Trial completion date
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
8ms
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (clinicaltrials.gov)
P3, N=1264, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Sep 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
8ms
KEYVIBE-006: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) (clinicaltrials.gov)
P3, N=611, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2029 --> Aug 2026 | Trial primary completion date: Sep 2028 --> Aug 2026
Trial completion date • Trial primary completion date
|
cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • vibostolimab/pembrolizumab (MK-7684A)
10ms
KEYVIBE 007: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (clinicaltrials.gov)
P3, N=739, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2027 --> Jan 2026 | Trial primary completion date: Jun 2026 --> Sep 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)
Share via
